Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets

Naoki Tanimine, Sharon K. Germana, Martin Fan, Keli L Hippen, Bruce R Blazar, James F. Markmann, Laurence A. Turka, Bhavana Priyadharshini

Research output: Contribution to journalArticle

Abstract

Regulatory T cells (Tregs) are required for the maintenance of immune tolerance and adoptive Treg infusion therapy has become a promising approach to suppress immune responses in diseases such as autoimmunity and transplant rejection. However, one critical challenge of Treg therapy is the requirement of in vitro expansion of functionally stable Tregs while preventing either the contamination of T effector and/or emergence of unstable pathogenic Tregs. Recent studies showing distinct metabolic requirements of T effectors and Tregs suggest that manipulation of cell metabolism may be an attractive strategy to achieve this goal. Here we show that human thymically derived Tregs (tTregs) and in vitro induced Tregs (iTregs) from naive T cells engage glycolysis equivalently upon activation. However, inhibiting glucose metabolism via 2-deoxy-D-glucose (2DG) has distinct effects on each of these subsets. While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small. In contrast, 2DG treatment during iTreg induction modestly decreased their proliferation but strongly reduced both ICOS and FOXP3 expression. Importantly, both Treg subsets became insensitive to 2DG after day 3 post activation with little effect on either proliferation or FOXP3 expression while T conventional Th0 cells showed reduced proliferation under the same conditions. Moreover, 2DG treatment at day 3 did not impair the suppressive capabilities of Treg subsets. Collectively, these findings suggest that there is a distinct temporal requirement of glycolysis in each of the activated human Treg subsets and T conventional cells. Furthermore, 2DG treatment at the onset as a strategy to impair contaminating T effector cell proliferation is unfavorable for optimal Treg generation as well.

Original languageEnglish (US)
Article numbere0217761
JournalPloS one
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

T-cells
Deoxyglucose
T-Lymphocyte Subsets
Regulatory T-Lymphocytes
T-lymphocytes
glucose
Chemical activation
Glycolysis
Metabolism
glycolysis
Therapeutics
Immune Tolerance
Transplants
graft rejection
Cell proliferation
Graft Rejection
therapeutics
autoimmunity
metabolism
Autoimmunity

PubMed: MeSH publication types

  • Journal Article

Cite this

Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets. / Tanimine, Naoki; Germana, Sharon K.; Fan, Martin; Hippen, Keli L; Blazar, Bruce R; Markmann, James F.; Turka, Laurence A.; Priyadharshini, Bhavana.

In: PloS one, Vol. 14, No. 6, e0217761, 01.06.2019.

Research output: Contribution to journalArticle

Tanimine, N, Germana, SK, Fan, M, Hippen, KL, Blazar, BR, Markmann, JF, Turka, LA & Priyadharshini, B 2019, 'Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets', PloS one, vol. 14, no. 6, e0217761. https://doi.org/10.1371/journal.pone.0217761
Tanimine, Naoki ; Germana, Sharon K. ; Fan, Martin ; Hippen, Keli L ; Blazar, Bruce R ; Markmann, James F. ; Turka, Laurence A. ; Priyadharshini, Bhavana. / Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets. In: PloS one. 2019 ; Vol. 14, No. 6.
@article{34db98e669c04bc886708e26006249b6,
title = "Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets",
abstract = "Regulatory T cells (Tregs) are required for the maintenance of immune tolerance and adoptive Treg infusion therapy has become a promising approach to suppress immune responses in diseases such as autoimmunity and transplant rejection. However, one critical challenge of Treg therapy is the requirement of in vitro expansion of functionally stable Tregs while preventing either the contamination of T effector and/or emergence of unstable pathogenic Tregs. Recent studies showing distinct metabolic requirements of T effectors and Tregs suggest that manipulation of cell metabolism may be an attractive strategy to achieve this goal. Here we show that human thymically derived Tregs (tTregs) and in vitro induced Tregs (iTregs) from naive T cells engage glycolysis equivalently upon activation. However, inhibiting glucose metabolism via 2-deoxy-D-glucose (2DG) has distinct effects on each of these subsets. While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small. In contrast, 2DG treatment during iTreg induction modestly decreased their proliferation but strongly reduced both ICOS and FOXP3 expression. Importantly, both Treg subsets became insensitive to 2DG after day 3 post activation with little effect on either proliferation or FOXP3 expression while T conventional Th0 cells showed reduced proliferation under the same conditions. Moreover, 2DG treatment at day 3 did not impair the suppressive capabilities of Treg subsets. Collectively, these findings suggest that there is a distinct temporal requirement of glycolysis in each of the activated human Treg subsets and T conventional cells. Furthermore, 2DG treatment at the onset as a strategy to impair contaminating T effector cell proliferation is unfavorable for optimal Treg generation as well.",
author = "Naoki Tanimine and Germana, {Sharon K.} and Martin Fan and Hippen, {Keli L} and Blazar, {Bruce R} and Markmann, {James F.} and Turka, {Laurence A.} and Bhavana Priyadharshini",
year = "2019",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0217761",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets

AU - Tanimine, Naoki

AU - Germana, Sharon K.

AU - Fan, Martin

AU - Hippen, Keli L

AU - Blazar, Bruce R

AU - Markmann, James F.

AU - Turka, Laurence A.

AU - Priyadharshini, Bhavana

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Regulatory T cells (Tregs) are required for the maintenance of immune tolerance and adoptive Treg infusion therapy has become a promising approach to suppress immune responses in diseases such as autoimmunity and transplant rejection. However, one critical challenge of Treg therapy is the requirement of in vitro expansion of functionally stable Tregs while preventing either the contamination of T effector and/or emergence of unstable pathogenic Tregs. Recent studies showing distinct metabolic requirements of T effectors and Tregs suggest that manipulation of cell metabolism may be an attractive strategy to achieve this goal. Here we show that human thymically derived Tregs (tTregs) and in vitro induced Tregs (iTregs) from naive T cells engage glycolysis equivalently upon activation. However, inhibiting glucose metabolism via 2-deoxy-D-glucose (2DG) has distinct effects on each of these subsets. While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small. In contrast, 2DG treatment during iTreg induction modestly decreased their proliferation but strongly reduced both ICOS and FOXP3 expression. Importantly, both Treg subsets became insensitive to 2DG after day 3 post activation with little effect on either proliferation or FOXP3 expression while T conventional Th0 cells showed reduced proliferation under the same conditions. Moreover, 2DG treatment at day 3 did not impair the suppressive capabilities of Treg subsets. Collectively, these findings suggest that there is a distinct temporal requirement of glycolysis in each of the activated human Treg subsets and T conventional cells. Furthermore, 2DG treatment at the onset as a strategy to impair contaminating T effector cell proliferation is unfavorable for optimal Treg generation as well.

AB - Regulatory T cells (Tregs) are required for the maintenance of immune tolerance and adoptive Treg infusion therapy has become a promising approach to suppress immune responses in diseases such as autoimmunity and transplant rejection. However, one critical challenge of Treg therapy is the requirement of in vitro expansion of functionally stable Tregs while preventing either the contamination of T effector and/or emergence of unstable pathogenic Tregs. Recent studies showing distinct metabolic requirements of T effectors and Tregs suggest that manipulation of cell metabolism may be an attractive strategy to achieve this goal. Here we show that human thymically derived Tregs (tTregs) and in vitro induced Tregs (iTregs) from naive T cells engage glycolysis equivalently upon activation. However, inhibiting glucose metabolism via 2-deoxy-D-glucose (2DG) has distinct effects on each of these subsets. While 2DG treatment at the onset of activation significantly reduced the proliferation and expression of suppressive molecules such as ICOS and CTLA-4 in tTregs, its effect on FOXP3 expression was small. In contrast, 2DG treatment during iTreg induction modestly decreased their proliferation but strongly reduced both ICOS and FOXP3 expression. Importantly, both Treg subsets became insensitive to 2DG after day 3 post activation with little effect on either proliferation or FOXP3 expression while T conventional Th0 cells showed reduced proliferation under the same conditions. Moreover, 2DG treatment at day 3 did not impair the suppressive capabilities of Treg subsets. Collectively, these findings suggest that there is a distinct temporal requirement of glycolysis in each of the activated human Treg subsets and T conventional cells. Furthermore, 2DG treatment at the onset as a strategy to impair contaminating T effector cell proliferation is unfavorable for optimal Treg generation as well.

UR - http://www.scopus.com/inward/record.url?scp=85066741896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066741896&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0217761

DO - 10.1371/journal.pone.0217761

M3 - Article

C2 - 31170216

AN - SCOPUS:85066741896

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0217761

ER -